Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 7/20 | 0.39 |
| ▸ | MMP2 | P08253 | 6/20 | 0.39 |
| ▸ | MMP1 | P03956 | 5/20 | 0.39 |
| ▸ | MMP8 | P22894 | 5/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3838984 | 0.84 | MAPK1 (0.46) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL6642802 | 0.84 | MAPK1 (0.46) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL3841623 | 0.79 | CNR1 (0.40) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL3843570 | 0.79 | MEN1 (0.47) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL6643797 | 0.73 | MAPK1 (0.41) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL3843108 | 0.73 | MAPK1 (0.41) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL3838995 | 0.71 | CDK2 (0.42) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL3843269 | 0.71 | CNR1 (0.39) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL12713123 | 0.70 | MEN1 (0.42) | MEN1ALDH1A1KMT2AMAPK1AURKA | |
| SCHEMBL12713133 | 0.70 | MEN1 (0.42) | MEN1ALDH1A1KMT2AMAPK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1446387-B1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN CO LLC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| EP-1446387-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003045924-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | MEN1 4846/4885ALDH1A1 265/4885KMT2A 1010/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | MEN1 4846/4885ALDH1A1 265/4885KMT2A 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.